Literature DB >> 16550572

Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.

Paul J Michaels1, Elena F Brachtel, Brenna C Bounds, William R Brugge, Martha Bishop Pitman.   

Abstract

BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized cystic neoplasm of the pancreas, histologically classified by the degree of epithelial atypia and by the presence or absence of invasion of the cyst wall. To the authors' knowledge, the cytologic features of this neoplasm are poorly characterized, especially with respect to tumor grade.
METHODS: Thirty-three endoscopic ultrasound (EUS)-guided pancreatic fine-needle aspiration biopsy (FNAB) samples and 1 pancreatic duct brush specimen from 25 patients with a histologically confirmed IPMN were retrospectively reviewed. Blinded to tumor grade, background mucin, inflammation, necrosis, overall cellularity, the presence of gastrointestinal-contaminating epithelium, architecture of cell clusters, and nuclear and cellular morphology were evaluated. In cases in which special stains for mucin were performed, the diagnostic utility of these stains was assessed. These cytologic features were subsequently correlated with the histologic diagnosis.
RESULTS: The 34 cytology samples represented 4 adenomas, 15 IPMN-moderate dysplasias, 7 intraductal carcinomas, and 8 IPMNs with invasive carcinoma. Extracellular mucin was present in 97% of all cases; 53% had thick, viscous, "colloid-like" mucin. Special stains for mucin were positive in 6 of 11 cases (54%), helping to identify thin mucin in only 2 cases. Gastrointestinal contamination did not appear to create diagnostic difficulty due to an apparent dual (dysplastic-nondysplastic) epithelial population, but only 4 adenomas were evaluated in this study. Necrosis distinguished IPMN with carcinoma from IPMN-adenomas and IPMN with moderate dysplasia (P < .00001), and was more often observed with invasion than IPMN-carcinoma in situ (P < .05). Tight epithelial cell clusters with hyperchromatic nuclei and a high nuclear to cytoplasmic ratio was more significant in IPMN of at least moderate dysplasia (P = .03). Pale nuclei with parachromatin clearing was found to be a nuclear feature that was suspicious for at least carcinoma in situ (P < .001). In addition, significant background inflammation (neutrophils and histiocytes) was found to be more characteristic of IPMN with at least carcinoma in situ (P = .002).
CONCLUSIONS: The presence of thick, "colloid-like" mucin is noted in half of the IPMN cases, but was not found to be specific to grade. The absence of such mucin does not exclude an IPMN. The presence of tight epithelial cell clusters is consistent with a neoplasm of at least moderate dysplasia, and abundant background inflammation and parachromatin clearing correlated with the presence of at least carcinoma in situ. Necrosis was the only feature found to be strongly suggestive of invasion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16550572     DOI: 10.1002/cncr.21838

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

Review 1.  Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas with Situs Inversus Totalis-Case Report with Review of Literature.

Authors:  Shailesh Mohandas; Richard Dickson-Lowe; Nariman Karanjia
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 2.  Diagnosis and management of cystic lesions of the pancreas.

Authors:  William R Brugge
Journal:  J Gastrointest Oncol       Date:  2015-08

Review 3.  [Classification and malignant potential of pancreatic cystic tumors].

Authors:  I Esposito; A M Schlitter; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

4.  A new approach to managing intraductal papillary mucinous pancreatic neoplasms.

Authors:  Paula Ghaneh; John Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

5.  The value of cyst fluid analysis in the pre-operative evaluation of pancreatic cysts.

Authors:  Martha Bishop Pitman; William R Brugge; Andrew L Warshaw
Journal:  J Gastrointest Oncol       Date:  2011-12

6.  Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia.

Authors:  Terry K Morgan; Karin Hardiman; Christopher L Corless; Sandra L White; Robert Bonnah; Henry Van de Vrugt; Brett C Sheppard; Markus Grompe; Ediz F Cosar; Philip R Streeter
Journal:  Cancer Cytopathol       Date:  2012-07-18       Impact factor: 5.284

7.  Routine Cyst Fluid Cytology Is Not Indicated in the Evaluation of Pancreatic Cystic Lesions.

Authors:  Lawrence A Shirley; Jon Walker; Somashekar Krishna; Samer El-Dika; Peter Muscarella; E Christopher Ellison; Carl R Schmidt; Mark Bloomston
Journal:  J Gastrointest Surg       Date:  2016-05-26       Impact factor: 3.452

8.  Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts.

Authors:  Muriel Genevay; Mari Mino-Kenudson; Kurt Yaeger; Ioannis T Konstantinidis; Cristina R Ferrone; Sarah Thayer; Carlos Fernandez-del Castillo; Dushyant Sahani; Brenna Bounds; David Forcione; William R Brugge; Martha Bishop Pitman
Journal:  Ann Surg       Date:  2011-12       Impact factor: 12.969

Review 9.  Management of mucin-producing cystic neoplasms of the pancreas.

Authors:  Stefan Fritz; Andrew L Warshaw; Sarah P Thayer
Journal:  Oncologist       Date:  2009-02-11

Review 10.  [Computed tomography of pancreatic tumors].

Authors:  L Grenacher; M Klauss
Journal:  Radiologe       Date:  2009-02       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.